MA30954B1 - Procede de generation d'anticorps actifs contre un antigene de resistance, anticorps obtenus par ce procede et utilisations de ces anticorps - Google Patents

Procede de generation d'anticorps actifs contre un antigene de resistance, anticorps obtenus par ce procede et utilisations de ces anticorps

Info

Publication number
MA30954B1
MA30954B1 MA31800A MA31800A MA30954B1 MA 30954 B1 MA30954 B1 MA 30954B1 MA 31800 A MA31800 A MA 31800A MA 31800 A MA31800 A MA 31800A MA 30954 B1 MA30954 B1 MA 30954B1
Authority
MA
Morocco
Prior art keywords
tumor
generating active
resistant
resistance
antibodies
Prior art date
Application number
MA31800A
Other languages
English (en)
Inventor
Liliane Goetsch
Alexandra Jouhanneaud
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of MA30954B1 publication Critical patent/MA30954B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'INVENTION CONCERNE L'UTILISATION D'UN PRODUIT DE BROYAGE ET/OU D'UNE SUSPENSION ET/OU D'UN LYSAT CELLULAIRE PROVENANT D'UNE TUMEUR RÉSISTANTE À AU MOINS UN COMPOSÉ ANTI-TUMORAL À DES FINS D'IMMUNISATION ET DE GÉNÉRATION IN VITRO D'UN ANTICORPS, OU D'UN DE SES FRAGMENTS FONCTIONNELS, POUR LUTTER CONTRE UN ANTIGÈNE TUMORAL SPÉCIFIQUEMENT EXPRIMÉ À LA SURFACE DE LA TUMEUR RÉSISTANTE ET POUVANT ÉVENTUELLEMENT INTERVENIR DANS LA RÉSISTANCE DE LA TUMEUR RÉSISTANTE. L'INVENTION PORTE EN PARTICULIER SUR DES ANTICORPS OBTENUS PAR CE PROCÉDÉ TELS QUE LES ANTICORPS 1A6, 1A9, 2E11, 3C11 ET 3G7, AINSI QUE SUR LEUR UTILISATION POUR TRAITER LE CANCER.
MA31800A 2006-09-28 2009-04-17 Procede de generation d'anticorps actifs contre un antigene de resistance, anticorps obtenus par ce procede et utilisations de ces anticorps MA30954B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0608514A FR2906533B1 (fr) 2006-09-28 2006-09-28 Procede de generation d'anticorps actifs contre un antigene de resistance,anticorps obtenus par ledit procede et leurs utilisations

Publications (1)

Publication Number Publication Date
MA30954B1 true MA30954B1 (fr) 2009-12-01

Family

ID=38164542

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31800A MA30954B1 (fr) 2006-09-28 2009-04-17 Procede de generation d'anticorps actifs contre un antigene de resistance, anticorps obtenus par ce procede et utilisations de ces anticorps

Country Status (22)

Country Link
US (2) US8241646B2 (fr)
EP (4) EP2081592B1 (fr)
JP (1) JP5774276B2 (fr)
KR (1) KR101504770B1 (fr)
CN (1) CN101516394B (fr)
AR (1) AR063061A1 (fr)
AU (1) AU2007312437C1 (fr)
BR (1) BRPI0717246A2 (fr)
CA (1) CA2663561A1 (fr)
FR (1) FR2906533B1 (fr)
HK (1) HK1131063A1 (fr)
IL (1) IL197790A (fr)
MA (1) MA30954B1 (fr)
MX (1) MX2009003245A (fr)
NO (1) NO20091613L (fr)
NZ (1) NZ576420A (fr)
RU (1) RU2515904C2 (fr)
TN (1) TN2009000102A1 (fr)
TW (1) TWI516276B (fr)
UA (1) UA102812C2 (fr)
WO (1) WO2008046724A1 (fr)
ZA (1) ZA200902697B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7241444B2 (en) * 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
CU23736A1 (es) 2009-05-04 2011-11-15 Centro Inmunologia Molecular Anticuerpos que reconocen sulfatidos y proteoglicanos sulfatados y su uso
WO2011004899A1 (fr) * 2009-07-06 2011-01-13 Takeda Pharmaceutical Company Limited Anticorps de modification d’une maladie cancéreuse
WO2011066417A2 (fr) * 2009-11-24 2011-06-03 Carnegie Mellon University Anticorps et conjugués pour des modulateurs d'angiogenèse
EP2635602B1 (fr) 2010-11-03 2016-09-07 Argen-X Nv Anticorps anti c-met
US9255595B2 (en) * 2011-04-29 2016-02-09 Bae Systems Information And Electronic Systems Integration Inc. Optical dome bezel
EP2773660A2 (fr) 2011-11-03 2014-09-10 Argen-X B.V. Antigenes chimeres humains chameaux et leur utilisation
KR102218494B1 (ko) 2013-03-15 2021-02-19 인트린식 라이프사이언시스, 엘엘씨 항-헵시딘 항체 및 그의 용도
TW201613615A (en) 2014-06-30 2016-04-16 Academia Sinica Antagonists for interleukin-17 receptor B (IL-17RB) and its ligand IL-17B for cancer therapy
EP3197915A4 (fr) 2014-09-22 2018-12-19 Intrinsic Lifesciences LLC Anticorps anti-hepcidine humanisés et utilisations de ceux-ci
AR104413A1 (es) * 2015-04-27 2017-07-19 Pf Medicament Anticuerpo de igf-1r y su utilización para diagnosticar cáncer
TWI716400B (zh) * 2015-04-27 2021-01-21 法商皮爾法伯製藥公司 新穎的igf-1r抗體及其用於癌症診斷之用途（二）
JP6976241B2 (ja) * 2015-08-14 2021-12-08 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. 抗ｔｉｇｉｔ抗体
CN108368175B (zh) * 2015-09-29 2021-08-06 上海张江生物技术有限公司 Pd-1抗体及其用途
GB2547179A (en) * 2015-10-26 2017-08-16 Quethera Ltd Genetic construct

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6261596A (ja) * 1985-09-11 1987-03-18 Japan Found Cancer Res 薬剤耐性癌に関するモノクロ−ナル抗体およびその製造
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB8924581D0 (en) 1989-11-01 1989-12-20 Pa Consulting Services Bleaching of hair
AU633698B2 (en) 1990-01-12 1993-02-04 Amgen Fremont Inc. Generation of xenogeneic antibodies
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
WO1994004679A1 (fr) 1991-06-14 1994-03-03 Genentech, Inc. Procede pour fabriquer des anticorps humanises
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
NZ246818A (en) * 1992-02-06 1997-07-27 Merrell Dow Pharma Use of tetraphenylethylene and/or pyridyltriphenyl ethylene derivatives to prepare medicaments for treating tumours
IT1257893B (it) * 1992-06-17 1996-02-16 Ist Superiore Sanita Anticorpi monoclonali che riconoscono un epitopo della p-glicoproteina umana.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5503984A (en) * 1993-04-13 1996-04-02 Health Research, Inc. Hybridoma producing monoclonal antibody F4 which specifically binds to multidrug resistant P-glycoprotein and assays for detection of P-glycoprotein
US6245898B1 (en) * 1998-06-15 2001-06-12 The Research Foundation Of State University Of New York Monoclonal antibodies that recognize antigens associated with tumor metastasis
US7303760B2 (en) 1999-04-23 2007-12-04 Alza Corporation Method for treating multi-drug resistant tumors
DK1461359T3 (da) 2002-01-18 2007-07-09 Pf Medicament Hidtil ukendte anti-IGF-IR-antistoffer og anvendelser deraf
WO2004026293A2 (fr) 2002-09-20 2004-04-01 Wyeth Holdings Corporation Methode de traitement de tumeurs resistantes
CA2540165A1 (fr) * 2003-10-08 2005-04-21 Ebioscience Reactifs endogenes se liant a l'immunoglobuline et procedes d'elaboration de ceux-ci
PT1720540E (pt) 2004-02-18 2008-09-10 Gpc Biotech Ag Métodos de tratamento de tumores resistentes ou refractários
EP1742060A1 (fr) * 2005-01-24 2007-01-10 DIGILAB BioVisioN GmbH Acides nucléiques et peptides de TIF1-beta pour le diagnostic et le traitement du cancer et des maladies colorectals cancéreuses.

Also Published As

Publication number Publication date
AU2007312437B2 (en) 2014-01-23
EP2491945B9 (fr) 2017-03-08
WO2008046724A1 (fr) 2008-04-24
ZA200902697B (en) 2010-04-28
US8241646B2 (en) 2012-08-14
IL197790A0 (en) 2011-08-01
EP2491945A1 (fr) 2012-08-29
CN101516394B (zh) 2014-07-30
JP2010504743A (ja) 2010-02-18
EP2494984A1 (fr) 2012-09-05
US20100146650A1 (en) 2010-06-10
EP2081592A1 (fr) 2009-07-29
UA102812C2 (ru) 2013-08-27
EP2491945B1 (fr) 2016-12-07
KR20090057469A (ko) 2009-06-05
TN2009000102A1 (en) 2010-08-19
NO20091613L (no) 2009-06-26
KR101504770B1 (ko) 2015-03-20
AU2007312437A1 (en) 2008-04-24
TW200822934A (en) 2008-06-01
EP2497491B1 (fr) 2017-03-01
FR2906533A1 (fr) 2008-04-04
BRPI0717246A2 (pt) 2013-10-08
MX2009003245A (es) 2009-07-07
US20130028835A1 (en) 2013-01-31
AR063061A1 (es) 2008-12-23
IL197790A (en) 2016-10-31
EP2494984B1 (fr) 2017-01-04
EP2497491A1 (fr) 2012-09-12
NZ576420A (en) 2012-05-25
FR2906533B1 (fr) 2013-02-22
US8808667B2 (en) 2014-08-19
AU2007312437C1 (en) 2014-04-10
EP2081592B1 (fr) 2016-01-13
HK1131063A1 (en) 2010-01-15
JP5774276B2 (ja) 2015-09-09
CA2663561A1 (fr) 2008-04-24
RU2009114682A (ru) 2010-11-20
CN101516394A (zh) 2009-08-26
RU2515904C2 (ru) 2014-05-20
TWI516276B (zh) 2016-01-11

Similar Documents

Publication Publication Date Title
MA30954B1 (fr) Procede de generation d'anticorps actifs contre un antigene de resistance, anticorps obtenus par ce procede et utilisations de ces anticorps
NZ595235A (en) Compositions and methods for increasing muscle growth
JP2019107018A5 (fr)
MA43028B1 (fr) Anticorps bispécifiques pour pd1 et tim3
MX2019007848A (es) Anticuerpos anti-pd-1 y usos de los mismos.
DE602006006200D1 (de) Antikörper gegen 25-hydroxyvitamin d
MX2009008140A (es) Vacunas a base de antigeno dirigido a dcir expresado en celulas que presentan antigeno.
WO2010017103A3 (fr) Anticorps monoclonaux anti-nkg2d humain entièrement humains
PE20141017A1 (es) Anticuerpos del cea
MA31984B1 (fr) Formulation d'anticorps
JP2014509187A5 (fr)
WO2008156763A3 (fr) Anticorps monoclonaux neutralisants humains dirigés contre le virus de la grippe a h5n1
WO2007073499A3 (fr) Molecules epha2 bite et leur utilisation
UA116614C2 (uk) Антитіло до фактора d і його застосування
WO2010010467A3 (fr) Anticorps neutralisant anti-virus influenza a et leurs utilisations
UA92505C2 (ru) Композиции на основе антитела против cd3
NZ592214A (en) Improved Interleukin-6 receptor antibody molecule
MX2009008608A (es) Anticuerpos monoclonales anti-cxcl13.
MA42895A (fr) Cellules modifiées pour thérapie cellulaire adoptive
GB0619291D0 (en) Altered antibodies
WO2008060367A3 (fr) Anticorps humains qui se lient au cxcr4, et leurs utilisations
WO2004005470A3 (fr) Anticorps contre muc1 et muc16 non liberees et leurs utilisations
PE20170903A1 (es) Conjugados de farmacos con anticuerpos anti-cdh6
NZ597023A (en) Monoclonal antibodies that bind to hGM-CSF and medical compositions comprising same
AR085334A1 (es) Inmunoterapia mejorada, composicion farmaceutica, kit